TIGIT and cancer: In addition, TIGIT, which is a T-cell immune receptor with Ig and ITIM domains (31) and was upregulated in the high-immunity, has been recently identified as an attractive cancer immunotherapy target, because of its key role in interactions between the cells within the tumor microenvironment.